Mucopolysaccharidosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Mucopolysaccharidosis stocks.

Mucopolysaccharidosis Stocks Recent News

Date Stock Title
Apr 26 BMRN BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript
Apr 26 BMRN BioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations
Apr 25 RARE Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
Apr 25 BMRN Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Apr 25 BMRN BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Apr 25 BMRN BioMarin drops drug programs in pipeline cull
Apr 25 BMRN Q1 2024 Biomarin Pharmaceutical Inc Earnings Call
Apr 25 BMRN Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...
Apr 25 BMRN BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript
Apr 25 BMRN BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation
Apr 24 BMRN BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Apr 24 BMRN BioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS Estimates
Apr 24 BMRN BioMarin updated 2024 guidance sees EPS raise, but no change to revenue
Apr 24 BMRN BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Apr 24 BMRN BioMarin Pharmaceutical Non-GAAP EPS of $0.71 beats by $0.11, revenue of $648.83M misses by $2.98M
Apr 24 BMRN BioMarin Reports Record Financial Results for the First Quarter 2024
Apr 24 RGNX REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Apr 23 BMRN BioMarin Pharmaceutical Q1 2024 Earnings Preview
Apr 23 BMRN Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
Apr 23 BMRN AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Mucopolysaccharidosis

Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans (GAGs). These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. GAGs (formerly called mucopolysaccharides) are also found in the fluids that lubricate joints.
Individuals with mucopolysaccharidosis either do not produce enough of one of the eleven enzymes required to break down these sugar chains into simpler molecules, or they produce enzymes that do not work properly. Over time, these GAGs collect in the cells, blood and connective tissues. The result is permanent, progressive cellular damage which affects appearance, physical abilities, organ and system functioning.
The mucopolysaccharidoses are part of the lysosomal storage disease family, a group of more than 40 genetic disorders that result when the lysosome organelle in animal cells malfunctions. The lysosome can be thought of as the cell's recycling center because it processes unwanted material into other substances that the cell can utilize. Lysosomes break down this unwanted matter via enzymes, highly specialized proteins essential for survival. Lysosomal disorders like mucopolysaccharidosis are triggered when a particular enzyme exists in too small an amount or is missing altogether.

Browse All Tags